At a Beijing research hospital, scientists have fashioned a single molecular tool that can both find and destroy kidney cancer tumors — a convergence of diagnosis and therapy that medicine has long sought. The compound targets a protein that kidney cancer cells overproduce, allowing clinicians to first map the disease and then deliver radiation with unusual precision. For patients whose cancers have outrun immunotherapy and surgery, this approach represents not merely a new drug but a new philosophy of treatment — one that listens to the tumor's own biology before striking it.
New radiotheranostic pair shows promise for metastatic kidney cancer treatment
Patients with metastatic kidney cancer who had progressed on standard therapy participated in clinical trials; gastric toxicity was observed in treatment.